Patients Stopping Slimming Jabs Gain Back Weight at a Quadrupled Rate Compared to Those on Conventional Diets
Fresh analysis indicates that patients who stop using popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle plans.
Research printed in a major health publication demonstrates that while overweight people can lose substantial amounts of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users using these drugs should be cognizant of the risk of quick weight regain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to original mass in about one and a half years.
Weighing Approaches
The research, which reviewed dozens of studies involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
The team note that individuals who lose weight through dieting usually experience a slower creep back—perhaps 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Experts suggest the way of the jabs accounts for the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating far more likely."
A Lifelong Disease?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, given the significant potential of relapse, the treatment might need to be long-term.
This view is echoed by drug manufacturers, who note that the findings "highlight the long-term character of obesity," similar to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the medication explain a intense resurgence of hunger.
"It was like something flipping and I was suddenly extremely hungry," described one woman.
This challenge is worsened if patients have not adopted lasting dietary or behavioural modifications during treatment.
Growing Use
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while the jabs are powerful agents for weight loss, they are not a magic solution and long-term success relies on ongoing lifestyle management.
